MedTrace Logo

Safety and Efficacy of γδ T Cell Against Gastric Cancer

NCT02585908 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-11-13

No results posted yet for this study

Summary

In this study, safety and effects of γδT cells on human gastric cancer are going to be investigated.

Conditions

Interventions

BIOLOGICAL

CIK

CIK cells will be used against tumor cells.

BIOLOGICAL

γδ T

γδ T cells will be used against tumor cells.

BIOLOGICAL

CIK and γδ T

CIK and γδ T cells will be used against tumor cells.

Sponsors & Collaborators

  • Beijing Doing Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • li gangyi, master · Beijing Doing Biomedical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585908 on ClinicalTrials.gov